Search

Rob is a Chief Technology Officer based in Manchester, with over 20 years’ experience leading technology, software development and digital transformation.

• Trustee
• Written

Raise money to help support people affected by inherited sight loss to lead better lives today and accelerate the search for treatments for the future.

Our monthly e-Newsletter featuring the latest updates from Retina UK.

• e-Newsletter
• Audio
• Written

Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.

The following questions are often asked by people contacting Retina UK.

Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.

Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.

• News
• Retinitis pigmentosa

Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.

• News
• Usher syndrome

Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.

• News
• Leber congenital amaurosis (LCA)